orvida
1 known investors
Orvida Pharma is a clinical-stage biotech developing disease-modifying oral and topical TRPV3 inhibitor therapies for rare, severe genetic skin diseases such as Olmsted Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, and Ichthyosis. Its lead candidates include Ontivatrep (oral) and KM-001 (topical), targeting conditions with significant unmet patient needs.
Investors · 1
Frequently asked questions
- What does orvida do?
- Orvida Pharma is a clinical-stage biotech developing disease-modifying oral and topical TRPV3 inhibitor therapies for rare, severe genetic skin diseases such as Olmsted Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, and Ichthyosis. Its lead candidates include Ontivatrep (oral) and KM-001 (topical), targeting conditions with significant unmet patient needs.
- Who are orvida's investors?
- orvida's investors include BRM Capital.